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Phosphatidylinositol-5-Phosphate Activation
and Conserved Substrate Specificity of the
Myotubularin Phosphatidylinositol 3-Phosphatases
displayed activity toward PtdIns3P and PtdIns(3,5)P2,
but not the other naturally occurring phosphoinositides
(Figure 1A). The activity toward PtdIns(3,5)P2 adds a
novel substrate specificity for MTM1 [6] and is consis-
tent with reports that MTMR2 and MTMR3 use PtdIns3P
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Am Klopferspitz 18a and PtdIns(3,5)P2 as substrates [10, 11]. Purified MTMR6
showed the same substrate specificity as MTM1 (FigureMartinsried, 82152
Germany 1C), while the active site mutant protein MTMR6C336S
lacked any detectable activity toward either PtdIns3P2 School of Biosciences
University of Birmingham or PtdIns(3,5)P2. To confirm that MTM1 hydrolyses
PtdIns(3,5)P2, we performed an alternate analysis of activ-The Medical School
Birmingham B15 2TT ity described previously for MTMR3 [10]. This assay is
carried out in living yeast cells and is useful for establishing3 Physiological Laboratory
University of Liverpool 3-phosphatase activity against PtdIns(3,5)P2, since it
allows detection of the reaction product PtdIns5P, whichCrown Street
Liverpool L69 3BX is not normally detectable in yeast [10, 12, 13]. In control
yeast, no PtdIns5P was observed, whereas, in MTM1-United Kingdom
expressing yeast, a peak of PtdIns5P was generated, pre-
sumably by 3-phosphatase activity against PtdIns(3,5)P2
(Figure 1C). In accordance with this interpretation, in-Summary
creased PtdIns5P production was seen when cellular lev-
els of PtdIns(3,5)P2 were increased following osmoticPhosphoinositides control many different processes
shock (Figure 1C; [10, 12, 13]). Like MTMR2 and MTMR3,required for normal cellular function [1, 2]. Myotubular-
MTM1 and MTMR6 therefore utilize both PtdIns3P andins are a family of Phosphatidylinositol 3-phosphate
PtdIns(3,5)P2 as substrates, suggesting that this is a(PtdIns3P) phosphatases identified by the positional
general property of the myotubularins.cloning of the MTM1 gene in patients suffering from
To further investigate the properties of MTM1 andX-linked myotubular myopathy and the MTMR2 gene in
MTMR6, we performed a kinetic analysis of their enzymepatients suffering from the demyelinating neuropathy
activity with PtdIns3P and PtdIns(3,5)P2 as substratesCharcot-Marie-Tooth disease type 4B [3–9]. MTM1 is
(Figure 2). For this analysis, we assumed that, like othera phosphatidylinositol phosphatase with reported
phosphatases, MTM1 and MTMR6 have a two-step re-specificity toward PtdIns3P [6, 7], while the related
action mechanism in which the rate-limiting step isproteins MTMR2 and MTMR3 hydrolyze both PtdIns3P
transfer of phosphate from the substrate to the activeand PtdIns(3,5)P2 [10, 11]. We have investigated MTM1
site cysteine, that this phosphoenzyme intermediate isand MTMR6 and find that they use PtdIns(3,5)P2 in
short lived, and that the second substrate water is inaddition to PtdIns3P as a substrate in vitro. The prod-
great excess [14]. Activity measurements were per-uct of PtdIns(3,5)P2 hydrolysis, PtdIns5P, causes
formed for MTM1 with PtdIns3P and PtdIns(3,5)P2 con-MTM1 to form a heptameric ring that is 12.5 nm in
centrations between 10 and 100 M (Figure 2). Plots ofdiameter, and it is a specific allosteric activator of
initial reaction velocity as a function of substrate con-MTM1, MTMR3, and MTMR6. A disease-causing muta-
centration should be hyperbolic if the enzyme obeystion at arginine 69 of MTM1 falling within a putative
Michaelis-Menten kinetics [15]; but, in this case, thepleckstrin homology domain reduces the ability of the
curves are hyperbolic for neither MTM1 (Figures 2A andenzyme to respond to PtdIns5P. We propose that the
2B) nor MTMR6 (Figure S2). The sigmoidal curves ofmyotubularin family of enzymes utilize both PtdIns3P
initial velocity as a function of substrate concentrationand PtdIns(3,5)P2 as substrates, and that PtdIns5P
obtained for MTM1 and MTMR6 are reminiscent of oligo-functions in a positive feedback loop controlling their
meric enzymes such as pyruvate kinase and isocitrateactivity. These findings highlight the importance of
dehydrogenase in the absence of their allosteric activa-regulated phosphatase activity for the control of phos-
tors and suggest cooperative substrate binding at multi-phoinositide metabolism.
ple sites [15]. One key point in the general theoretical
treatments of allostery is that the enzyme is assumed to
Results and Discussion be oligomeric to explain cooperative substrate binding
[15]. We therefore examined MTM1 and MTMR6 by gel
We investigated the phosphatase activities of MTM1 filtration and found that both enzymes have apparent
and MTMR6 toward phosphoinositides under defined molecular sizes consistent with a monomeric state in
conditions to determine their substrate specificity (Fig- the absence of substrate [16]. It was not practical to
ures 1 and S1 [the latter is available in the Supplemental perform the analysis in the presence of phosphoinosi-
Data available with this article online]). Purified MTM1 tides, and we could not exclude the possibility that the
substrate-induced oligomerization observed for en-
zymes such as D-amino acid oxidase occurs with myo-*Correspondence: barr@biochem.mpg.de
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tubularins [17]. While unusual, there are a number of
monomeric enzymes displaying allosteric regulation
[18], such as the ribonucleotide reductase of Lactobacil-
lus leichmannii that has a catalytic site where ribonucle-
otides bind and a discrete regulatory site for nucleotides
[19, 20]. To explain the sigmoidal curves of initial velocity
as a function of substrate concentration for MTM1, we
initially postulated that the substrate, PtdIns3P, is a
weak allosteric activator capable of binding at a regula-
tory site on the monomeric enzyme. By analogy with
ribonucleotide reductase, we felt it was unlikely that
PtdIns3P was the physiological activator, but that this
could be a related molecule. Non-substrate phospho-
inositides were therefore tested for their ability to acti-
vate MTM1. The activity of MTM1 toward 50 M
PtdIns3P was stimulated by 20 M PtdIns5P, while
PtdIns4P had no effect, and the other phosphoinositides
tested had little or an inhibitory effect (Figure S3A).
PtdIns5P activates the catalytic activity of MTM1 toward
both PtdIns3P and PtdIns(3,5)P2 (Figures 2C and 2D).
Additionally, the effect of PtdIns5P on PtdIns3P hydroly-
sis by MTM1 was also observed when long chain deriva-
tives of these phosphoinositides were incorporated into
liposomes (Figure 2E). Likewise, the activity of MTMR3
toward 50 M PtdIns3P was activated in the presence
of 20 M PtdIns5P (Figure 2F), while, under the same
conditions, the initial rate of reaction was increased for
MTMR6 although the sustained reaction velocity at later
time points was similar (Figure S3B). It is important to
note that PtdIns5P is not a substrate for these enzymes
(Figure 1; [10]), and we conclude that it acts as an alloste-
ric activator for MTM1, MTMR3, and possibly MTMR6.
When PtdIns(3,5)P2 is used as the substrate, PtdIns5P
is generated and could activate the enzyme by a positive
feedback mechanism. It is unlikely that such a regulatory
mechanism would exist to no effect, and this finding
supports the proposition that PtdIns(3,5)P2 represents
a physiologically relevant substrate for myotubularins. In
addition to localization to membrane subcompartments
such as plasma membrane ruffles [21], myotubularin
activity could also be compartmentalized by the avail-
ability of PtdIns5P. Thus, PtdIns3P and PtdIns(3,5)P2 in
membrane domains lacking PtdIns5P would be poor
substrates for myotubularins.
During our investigations of MTM1, MTMR3, and
MTMR6, we noticed that their catalytic activity showed
a sigmoidal dependence on enzyme concentration, sug-
gestive of oligomerization under reaction conditions.
MTM1 shows a 9-fold increase in initial reaction velocity
toward PtdIns3P when enzyme concentration is in-
creased from 15 to 30 nM (Figure 3A). To investigate
the potential oligomerization of MTM1 under reaction
conditions, we exploited the fact that mutations in the
catalytic cysteine of phosphatases are thought to abol-
ish catalytic activity without altering their substrate bind-
ing properties [14]. First, the activity of 30 nM MTM1
Figure 1. Substrate Specificity of MTM1 and MTMR6 In Vitro and a mutant form in which the catalytic cysteine was
(A) The activity of 30 nM MTM1 expressed in, and purified from, changed to serine were compared, and MTM1C375S was
insect cells toward 50 M phosphatidylinositol and the indicated
phosphoinositides was measured for 10 min at 37C (n  4).
(B) MTMR6 expressed in, and purified from, bacteria was assayed
in the same manner as MTM1 (n  4).
(C) As described previously [12, 13], cellular phosphoinositides were from yeast strains containing a control plasmid or an MTM1 expres-
extracted and analyzed by high-pressure liquid chromatography sion plasmid stimulated with 0.9 M NaCl for 10 min.
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Figure 2. PtdIns5P Is an Activator of MTM1 and MTMR3 In Vitro
(A and B) The activity of MTM1 toward the indicated concentrations of PtdIns3P and PtdIns(3,5)P2 was measured. Initial reaction velocities
were calculated from these time courses and are plotted against the respective substrate concentration.
(C and D) The activity of MTM1 toward 50 M PtdIns3P and 50 M PtdIns(3,5)P2 in the presence and absence of 20 M PtdIns5P was
measured (n  2).
(E) The activity of 15 nM MTM1 was tested toward control liposomes and liposomes containing 10 mol% of the indicated phosphoinositides
(n  4).
(F) The activity of MTMR3 toward 50 M PtdIns3P in the presence and absence of 20 M PtdIns5P was measured (n  2).
found to lack activity toward PtdIns3P, even in the pres- interacts with MTM1C375S in the presence of substrate
and that these oligomeric forms of the enzyme haveence of PtdIns5P (Figure 3B). To shift the equilibrium
from monomeric to oligomeric MTM1, catalytically dead increased activity compared to monomeric MTM1. To
visualize these oligomeric forms of MTM1, we analyzedMTM1C375S was titrated into assays containing 18 nM
MTM1, a concentration at which MTM1 shows approxi- enzyme reactions by negative stain electron microscopy
(Figure 3D). Catalytically inactive MTM1C375S was usedmately half maximal activity toward PtdIns3P and is thus
poised for activation (Figure 3A). The addition of 1.8 nM for these experiments to trap the substrate and activator
bound intermediates, since these are rapidly turned overMTM1C375S caused an increase in the activity of MTM1,
and this effect was already maximal when equimolar by the active enzyme. This analysis revealed that, under
activated conditions, MTM1 forms a heptameric ringMTM1C375S was used (Figure 3C). When MTM1C375S was
replaced by catalytically inactive MTMR6 or bovine se- structure that is on average 12.5 nm in diameter, and
that these ring structures are essentially absent priorrum albumin, these effects were not seen, indicating
that this is a specific effect of MTM1 (Figure S4). The to activation of MTM1 with PtdIns5P and substrate (Fig-
ure 3D).simplest explanation for this observation is that MTM1
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Figure 3. Activation of MTM1 by Oligomer-
ization
(A) MTM1 activity toward 50 M PtdIns3P
was determined at the indicated enzyme con-
centrations.
(B) The activity of 30 nM MTM1 or catalytic
site mutant MTM1C375S toward 50 M
PtdIns3P was determined in the presence
and absence of 20 M PtdIns5P.
(C) Catalytic site mutant MTM1C375S was ti-
trated into assays containing 18 nM MTM1
and 50 M PtdIns3P (n  2).
(D) Phosphatase assays containing 200 ng/
l MTM1C375S with either buffer (control) or 100
M PtdIns3P and 40 M PtdIns5P were incu-
bated for 5 min at 37C, then spotted onto
copper grids for staining with uranyl acetate
and visualization by electron microscopy. Im-
ages were taken at 35,000 magnification.
We then examined the sequence of MTM1 for con- quires 50 M PtdIns5P to achieve the same level of
activity (Figure 4B). This observation is consistent withserved basic residues associated with disease-causing
mutations in X-linked myotubular myopathy [22, 23], the idea that MTM1R69C shows a reduced level of activity
due to a mutation in its allosteric regulatory site andwhich, by analogy with pleckstrin homology (PH) do-
mains, could mediate the specific recognition of phos- has a reduced affinity for PtdIns5P. The amino-terminal
region of myotubularins contains a divergent PH domainphoinositides [24]. Candidate arginine residues at posi-
tions 69, 184, 241, 421, and histidine 469 of MTM1 were [9] that might be a binding site for PtdIns5P, since argi-
nine 69 of MTM1 lies within this domain and a basicmutated to the amino acids found in the disease state,
and the conserved arginines at positions 114 and 220 residue is conserved at this position in other myotubular-
ins. Consistent with this idea, another mutation at awere mutated to alanine. Corresponding mutant pro-
teins were tested for basal and PtdIns5P-stimulated ac- conserved site in this putative PH domain, MTM1K114A,
also shows a decreased response to PtdIns5P (Fig-tivity toward PtdIns3P (Figure 4A). Mutations at posi-
tions 220, 241, and 469 showed no activity (J.S. and ure 4B).
F.A.B, unpublished data), in agreement with previous Our results show that myotubularins have a common
reports that MTM1R241L is inactive [6, 25]. MTM1R184G and substrate specificity toward PtdIns3P and PtdIns(3,5)P2
MTM1R421Q could be stimulated by the addition of 20 M and identify a regulatory function for PtdIns5P. We pro-
PtdIns5P, but they showed only low levels of activity pose a model in which the monomeric myotubularins are
compared to MTM1, even at high enzyme concentration essentially catalytically inactive and binding of substrate
(Figure 4A). MTM1R69C had a lower activity than MTM1 phosphoinositide and the allosteric activator PtdIns5P
in the presence or absence of 20 M PtdIns5P, condi- triggers oligomerization and thus activates these en-
tions at which MTM1 is maximally active, but was more zymes.
active than the other mutants tested (Figure 4A). If the
reduced activity of MTM1R69C reflects a decreased affin-
Supplemental Dataity for the allosteric activator, then it should be possible
Supplemental Data including details of the experimental proceduresto increase MTM1R69C activity by titrating in PtdIns5P.
used, additional data relating to MTM1 and MTMR6 substrate speci-
We therefore tested the ability of PtdIns5P to activate 30 ficity and regulation, and control experiments is available upon re-
nM MTM1 and MTM1R69C (Figure 4B). MTM1 is maximally quest from the authors and at http://images.cellpress.com/supmat/
supmatin.htm.activated by 10–20 M PtdIns5P, while MTM1R69C re-
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Figure 4. Characterization of MTM1 Mutants Associated with Disease
(A) The activity of MTM1, MTM1R69C, and MTM1R184G toward 50 M Ptdins3P was determined as a function of time at the indicated enzyme
concentrations in the presence and absence of 20 M PtdIns5P. Initial reaction velocities were calculated from these time courses and are
plotted against the respective enzyme concentration.
(B) The activities of 30 nM MTM1, MTM1R69C, and MTM1K114A toward PtdIns3P were determined as a function of time in the presence of the
indicated concentrations of PtdIns5P and in its absence. Initial reaction velocities were calculated from these time courses and are plotted
against the respective PtdIns5P concentration.
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